Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Latest filing published 25 Aug 2026 for Allogene Therapeutics, Inc., €54k. Read the official filing
Filing timeline
BuySaleEarl Martin Douglas
Insider track record
Disclosed buys
0
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Earl Martin Douglas: trading record in brief
All filings by Earl Martin Douglas on record concern Allogene Therapeutics, Inc. In total, 7 filings cover trades dated from 14 August 2023 to 21 August 2026.
Every open-market trade on record is a sale: 3 sales worth €99k. Outside the open market, there are 4 share grants. 2026 to date brings no purchases and 2 sales.
Most recently, on 25 August 2026, the filings show an open-market sale worth €54k in Allogene Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Earl Martin Douglas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
29,697 shares@ US$2.12Common StockSEC:0001628280-26-058920:0
22,900 shares@ US$1.76100.0% of flowCommon StockSEC:0001362155-26-000002:0
6,404 shares@ US$1.7113.1% of flowCommon StockSEC:0001737287-25-000020:0
144,928 shares0Common StockSEC:0001737287-25-000009:0
28,310 shares@ US$2.78586.9% of flowCommon StockSEC:0001593968-24-001096:0
41,800 shares0Common StockSEC:0001593968-24-000196:0
108,958 shares0Common StockSEC:0001593968-23-001226:0
7 of 7 declarations
